This Article Full Text (PDF) All Versions of this Article: 35/1/156    most recent 01.STR.0000108266.11282.BFv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Felberg, R. A. Search for Related Content PubMed PubMed Citation Articles by Felberg, R. A. Pubmed/NCBI databases Medline Plus Health Information Stroke

(Stroke. 2004;35:156.)
© 2004 American Heart Association, Inc.

Original Contributions

Editorial Comment—The MOST Score: Modifying the Open-Artery "Good"–Closed-Artery "Bad" Approach to Thrombolysis Prognosis

Robert A. Felberg, MD, Guest Editor

Department of Neurology, Ochsner Foundation Clinic and Hospital, New Orleans, Louisiana

The rapidity and degree of recanalization has been shown to predict good outcome in thrombolysis of acute ischemic stroke.^1,2 However, despite complete recanalization, many patients continue to do poorly. Some never recover function, while others experience deterioration after improvement³ or symptomatic intracerebral hemorrhage. Conversely, many patients experience complete recovery despite continued vessel obstruction. Several clinical factors have been shown to predict poor outcome including continued arterial occlusion, slow recanalization, hyperglycemia, systolic hypertension, and early ischemic changes on the baseline CT scan.^4,5

In this report, Molina et al prospectively collected patients who presented with acute stroke syndromes with transcranial Doppler (TCD)-demonstrated middle cerebral artery occlusions and were treated using standard intravenous tissue plasminogen activator (tPA) protocols.⁶ Hemodynamic, radiologic, laboratory, and clinical data were examined, and 5 variables were found to be associated with good outcome (defined as a modified Rankin Scale score 2). These 5 variables (degree of recanalization, site of occlusion, early ischemic CT scan changes, severity of clinical presentation, and presence of moderate hypertension) were then assigned values as part of the scoring tool to predict outcome (the MOST [Multimodal Outcome Score for Stroke Thrombolysis] score).

In line with previous reports, the authors found that presence of recanalization had the strongest predictive value (OR, 4.11; P<0.001). Interestingly, 25% of patients without recanalization experienced a good outcome. Early ischemic changes on CT as measured by the Alberta Stroke Programme Early CT Score (ASPECTS) were found to be highly predictive as well (OR, 2.98; P=0.0253). These findings suggest that the strategy of rapid intervention with a goal of recanalization via intravenous or catheter-driven therapy is a valid one. However, no degree of flow restoration will bring back irreversibly damaged tissue possibly evidenced by early CT changes.⁷

The most intriguing finding is the variable of systolic blood pressures >150 leading to poor outcome. All of these patients would have had systolic blood pressures <185 and diastolic blood pressures <110 as part of the standard intravenous-tPA therapy guidelines.⁸ Outlier hypertensives would have been excluded. The role of blood pressure in stroke outcome is controversial.⁹ The results of the Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) trial¹⁰ and post-hoc analysis of the Heart Outcomes Prevention Evaluation (HOPE) stroke population¹¹ complicates this issue. Certainly, the question is out there—should we be actively lowering blood pressure in acute stroke? A well-designed trial is clearly needed.

There are some limitations to this study. The MOST score was derived by dichotomizing several variables such as degree of recanalization, systolic blood pressure, ASPECTS, and NIHSS in a manner that best enhances the effect for each criterion. Are these results as important when evaluating as continuous variables? All patients had TCD-determined occlusions in the middle cerebral artery territory. No consensus statement can be made about other arterial territories or the frequent patient who has no thrombus found. Long-term data were gathered by telephone in some cases, adding a variable to the quality of information. Finally, many of these patients received continuous TCD monitoring, which has been suggested to speed clot lysis and may have spuriously improved recanalization rates in this cohort.

How does this trial affect clinical practice? Many factors pointed out by the MOST score are already generally recognized as leading to poor outcome. Patients with large strokes, significant early ischemic changes on CT, and a large clot burden will do poorly in general, and these baseline characteristics cannot be altered. This leaves rapid recanalization and blood pressure as potential targets for therapy. The MOST score’s primary role is as a predictive and research tool. It may be useful to be able to offer an evidence-based prognostic assessment to families at the bedside following thrombolytic therapy. As pointed out by the authors, withholding intravenous tPA based on the MOST criteria is not advised.

	References

Top References

 

1. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, Grotta JC. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke. 2000; 31: 1812–1816.[Abstract/Free Full Text]
2. Felberg RA, Okon NJ, El-Mitwalli A, Burgin WS, Grotta JC, Alexandrov AV. Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke. Stroke. 2002; 33: 1301–1307.[Abstract/Free Full Text]
3. Alexandrov AV, Felberg RA, Demchuk AM, Christou I, Burgin WS, Malkoff M, Wojner AW, Grotta JC. Deterioration following spontaneous improvement: sonographic findings in patients with acutely resolving symptoms of cerebral ischemia. Stroke. 2000; 31: 915–919.[Abstract/Free Full Text]
4. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, Levine SR, and the Multicentre tPA Stroke Survey Group. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001; 57: 474–480.[Abstract/Free Full Text]
5. Barber PA, Demchuk AM, Zhang J, Buchan AM. ASPECTS Study Group: Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy: Alberta Stroke Programme Early CT Score. Lancet. 2000; 355: 1670–1674.[CrossRef][Medline] [Order article via Infotrieve]
6. Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabín J, for the CLOTBUST Investigators. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke. 2004; 35: 151–157.[Abstract/Free Full Text]
7. von Kummer R, Bourquain H, Bastianello S, Bozzao L, Manelfe C, Meier D, Hacke W. Early prediction of irreversible brain damage after ischemic stroke at CT. Radiology. 2001; 219: 95–100.[Abstract/Free Full Text]
8. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation. 1996; 94: 1167–1174.[Free Full Text]
9. Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, Broderick J, Kwiatkowski T, Lewandowski C, Haley EC, et al. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke. 1998; 29: 1504–1509.[Abstract/Free Full Text]
10. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P, Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003; 34: 1699–1703.[Abstract/Free Full Text]
11. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J. HOPE Investigators: Use of ramipril in preventing stroke: double blind randomised trial: Heart Outcomes Prevention Evaluation. BMJ. 2002; 324: 699–702.[Abstract/Free Full Text]

This article has been cited by other articles:

				R. C. Seet, E. C. Lim, B. P. Chan, B. K. Ong, and T. Dziedzic Serum Albumin Level as a Predictor of Ischemic Stroke Outcome Stroke, November 1, 2004; 35(11): 2435 - 2436. [Full Text] [PDF]

This Article Full Text (PDF) All Versions of this Article: 35/1/156    most recent 01.STR.0000108266.11282.BFv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Felberg, R. A. Search for Related Content PubMed PubMed Citation Articles by Felberg, R. A. Pubmed/NCBI databases Medline Plus Health Information Stroke